Nationwide Fund Advisors increased its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 11.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 32,906 shares of the biotechnology company’s stock after acquiring an additional 3,440 shares during the quarter. Nationwide Fund Advisors owned approximately 0.05% of Sarepta Therapeutics worth $1,493,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Alliancebernstein L.P. boosted its position in Sarepta Therapeutics by 63.3% during the second quarter. Alliancebernstein L.P. now owns 118,310 shares of the biotechnology company’s stock worth $3,988,000 after acquiring an additional 45,860 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in Sarepta Therapeutics during the second quarter worth approximately $630,000. Eagle Asset Management Inc. boosted its position in Sarepta Therapeutics by 33.4% during the second quarter. Eagle Asset Management Inc. now owns 798,412 shares of the biotechnology company’s stock worth $26,914,000 after acquiring an additional 200,103 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Sarepta Therapeutics by 96.4% during the second quarter. Russell Investments Group Ltd. now owns 75,170 shares of the biotechnology company’s stock worth $2,534,000 after acquiring an additional 36,897 shares during the last quarter. Finally, Asymmetry Capital Management L.P. boosted its position in Sarepta Therapeutics by 82.2% during the second quarter. Asymmetry Capital Management L.P. now owns 158,810 shares of the biotechnology company’s stock worth $5,353,000 after acquiring an additional 71,630 shares during the last quarter. Hedge funds and other institutional investors own 82.02% of the company’s stock.

In other news, SVP Shamim Ruff sold 11,500 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total value of $575,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the firm’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the transaction, the director now directly owns 13,333 shares in the company, valued at approximately $745,181.37. The disclosure for this sale can be found here. In the last three months, insiders sold 28,167 shares of company stock worth $1,497,619. Insiders own 9.60% of the company’s stock.

A number of brokerages recently issued reports on SRPT. Credit Suisse Group restated an “outperform” rating and set a $81.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Robert W. Baird restated a “buy” rating and set a $101.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, October 17th. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Piper Jaffray Companies restated an “overweight” rating and set a $55.00 target price (up previously from $50.00) on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $64.14.

Sarepta Therapeutics Inc (NASDAQ SRPT) opened at $55.97 on Tuesday. Sarepta Therapeutics Inc has a one year low of $26.26 and a one year high of $57.57. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. The company has a market cap of $3,620.00, a price-to-earnings ratio of -27.44 and a beta of 1.38.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The business had revenue of $45.95 million for the quarter, compared to the consensus estimate of $41.29 million. During the same quarter last year, the firm posted ($0.95) EPS. sell-side analysts forecast that Sarepta Therapeutics Inc will post -3.11 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Nationwide Fund Advisors Has $1.49 Million Position in Sarepta Therapeutics Inc (SRPT)” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://theolympiareport.com/2017/12/26/nationwide-fund-advisors-has-1-49-million-position-in-sarepta-therapeutics-inc-srpt.html.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.